Search
Deutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigationalIt is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis. … [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsFostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigational[L14867] It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir … [L14867,L14917] Targeting gp120 subunits is a new and novel therapeutic approach to HIV-1 infection, and the addition of attachment inhibitors, like temsavir, to the armament of therapies targeted against
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTetradecyl hydrogen sulfate (ester)
go.drugbank.com/drugs/DB11328ApprovedAlso noted was an unspecified number of episodes of epidermal necrosis without significant long-term effects and a 30% incidence of post-sclerosis pigmentation that resolved within a few months [L2035]
Potassium channel subfamily K member 10
go.drugbank.com/bio_entities/BE0013513TargetHumansVoltage sensing is coupled to K(+) electrochemical gradient in an 'ion flux gating' mode where outward but not inward ion flow opens the gate. … Permeable to other monovalent ions such as Rb(+) and Cs(+) (PubMed:26919430)
Polypeptides: Potassium channel subfamily K member 10Levobetaxolol
go.drugbank.com/drugs/DB09351ApprovedLevobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. … It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesNeisseria meningitidis serogroup b nada protein antigen
go.drugbank.com/drugs/DB10785ApprovedInvestigationalMixtures: BEXSERO 0,5 ML İM ENJEKSİYONLUK SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 10 ADET İĞNESİZ, BEXSERO 0,5 ML İM ENJEKSİYONLUK SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET 2 İĞNELİEstazolam
go.drugbank.com/drugs/DB01215ApprovedIllicitInvestigationalIt has been shown in some cases to be more potent than diazepam or nitrazepam.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Prosom Tab 1mg, Prosom Tab 2mgNeuronal acetylcholine receptor subunit alpha-10
go.drugbank.com/bio_entities/BE0000411TargetHumansEach nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, cation permeability, and binding to allosteric … The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane.
Polypeptides: Neuronal acetylcholine receptor subunit alpha-10Synonyms: NACHR alpha-10, Nicotinic acetylcholine receptor subunit alpha-10C-X-C motif chemokine 10
go.drugbank.com/bio_entities/BE0000934TargetHumansthem to the lesion site. … Plays thereby an important role during viral infections by stimulating the activation and migration of immune cells to the infected sites (By similarity).
Polypeptides: C-X-C motif chemokine 10Synonyms: IP-10, 10 kDa interferon gamma-induced proteinSolute carrier family 22 member 10
go.drugbank.com/bio_entities/BE0003652TransporterHumansPolypeptides: Solute carrier family 22 member 10